PHCCC has been shown to act as a group I metabotropic glutamate receptor antagonist with an IC50 of approximately 3 µM. This activity is 67 times more potent than (S)-4-carboxyphenylglycine (sc-203449). This compound has also demonstrated positive allosteric modulation for mGluR-4a, potentiates L-AP4-mediated inhibition of striatopallidal synaptic transmission in vitro, and displays anti-Parkinsonian effects in rat models.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.